Page 4 - Biocon

Stocks to Watch, May 8: Britannia, Coal India, Dabur, Voltas, RIL, L&T, PNB

Stocks to Watch on May 8, 2025: Here is a list of stocks that will be on investors' and traders' radar on Thursday, May 8, 2025

Biocon Biologics secures multiple market access coverage for Yesintek in US

Biocon Biologics' biosimilar Yesintek is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, and promises a cost-effective treatment

Syngene Q4 results: PAT down 3%, revenue from ops up 11% to ₹1,018 cr

Bains further noted that after a subdued first half, impacted by a sector-wide downturn in US biotech funding, the second half of the year showed signs of recovery

Biocon subsidiary secures permission to launch eye medicine Yesafili in US

Agreement enables company to make 'strategic entry' in ophthalmology sector in the US, it says

Biocon Biologics signs deal, gets market entry for Yesafili in US by 2026

Biocon Biologics on Tuesday said it has inked a settlement and licensing pact with Regeneron, paving the way to commercialise its biosimilar product Yesafili in the US. Yesafili, a vascular endothelial growth factor (VEGF) inhibitor used to treat several types of ophthalmology conditions, is a biosimilar of its reference product Eylea (aflibercept). Biocon Biologics and Regeneron executed the settlement agreement to dismiss the pending appeal at the US Court of Appeals for the Federal Circuit (USCAFC) and the pending litigation at the US District Court for the Northern District of West Virginia, Clarksburg Division, Biocon Biologics said in a statement. The agreement enables the company, a unit of Biocon Ltd, to launch its product in the US in the second half of 2026 or earlier in certain circumstances, it added. The terms of the settlement are confidential, it stated. "This settlement clears the path for Biocon Biologics to be among the first to bring a reliable, high-quality ..

Biocon subsidiary gets USFDA nod for Everolimus tablets; share zooms 6%

The rise in the Biocon share price came after its wholly-owned unit, Biocon Pharma, received USFDA nod for Everolimus tablets.

Biocon Biologics gets US FDA nod for Jobevne, expands oncology portfolio

Jobevne works by blocking a protein called VEGF, which helps tumours grow new blood vessels

Biocon, Cipla: Nifty Pharma down 6% as US eyes possible tariffs on sector

Adding to the worries of investors, US is looking for possible tariffs on the pharmaceutical goods

Peter Bains steps down as Group CEO of Biocon, to serve Syngene's MD & CEO

Furthermore, Biocon has scheduled a board meeting on April 4 to discuss and approve fundraising for its commercial business

Biocon gains 2% on US FDA nod for ANDA Norepinephrine Bitartrate Injection

The company's subsidiary has received approval from the US Food and Drug Administration (US FDA) for its ANDA Norepinephrine Bitartrate Injection USP, 4 mg/4 mL (1 mg/mL) single-dose vial

Syngene International acquires its first biologics unit in US for $36.5 mn

The facility, equipped with multiple monoclonal antibody (mAbs) manufacturing lines, comes for a deal value of $36.5 million

Biocon Biologics, Civica partner to expand Insulin Aspart access in the US

Biocon Biologics' own Insulin Aspart drug product for the US is currently under review by the US Food and Drug Administration (FDA)

Here's why Biocon share price popped 3% in trade on March 5; details here

The rise in Biocon share price came after the company announced that its wholly-owned subsidiary, Biocon Pharma, has received final approvals for Lenalidomide capsules and Dasatinib tabs from USFDA

Stocks to Watch, March 5: Adani Wilmar, Coforge, Biocon, Ola Electric, RVNL

Biocon: The company's subsidiary, Biocon Pharma, has received USFDA approvals for Lenalidomide capsules and Dasatinib tablets, and tentative approval for Rivaroxaban tablets

Biocon launches drug Liraglutide for diabetes, Biolide for obesity in UK

Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK. The GLP-1 peptide, Liraglutide, will be marketed in the UK under the brand names Liraglutide Biocon for diabetes and Biolide for chronic weight management, the company said in a statement. The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, earlier this year, making Biocon Ltd the first generics company to obtain approval for gLiraglutide in a major regulated market, it added. "The timely launch will offer healthcare providers and patients affordable access to this drug and help fulfil an unmet need," Biocon CEO and MD Siddharth Mittal said. The company will continue to focus its efforts towards expanding the reach of gLiraglutide into other European markets, the US and select geographies, he added. Glucagon-like peptide-1 (GLP-1) are medications that help lower blood sugar levels and promote weight loss. Liraglutid

Biocon share price up 2% as arm launches Yesintek in US; check details here

Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available to patients in US

Stocks to watch, Feb 25: M&M, Ireda, Nestle India, Airtel, Biocon

Stocks to watch today: Mahindra and Mahindra has increased its market share to 43.8 pr cent in the domestic tractor market despite a challenging year

Biocon Biologics launches biosimilar alternative to Stelara in the US

YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a cost-effective treatment for chronic autoimmune diseases

Indian drugmakers face risks as Trump eyes tariffs on US imports of pharma

The company relies on its key generic drugs in oncology and immunology therapies for sales in the region, which rose 28 per cent from a year earlier

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports